TREM2 target drugs are still early in their development, but their ability to alter TREM2 in early stages of Alzheimer’s disease has been found to promote cell survival and decrease amyloid levels in the brain. This evidence concerns the gene TREM2 and early-onset autosomal dominant Alzheimer disease.